Literature DB >> 14577919

A comparison of targeting performance of oncoretroviral versus lentiviral vectors on human keratinocytes.

Fernando Serrano1, Marcela Del Rio, Fernando Larcher, Marta Garcia, Evangelina Muñoz, María José Escamez, Marta Muñoz, Alvaro Meana, Antonio Bernad, José Luis Jorcano.   

Abstract

The epidermis, like other rapidly renewing tissues, relies on a stem cell compartment to undergo constant regeneration. In order to develop realistic and long-lasting therapeutic approaches for some skin disorders, gene transfer to these critical cells must be obtained. While efficient retroviral ex vivo targeting and transgene integration in human keratinocytes is tightly dependent on proliferation, transferring genetic information to quiescent cells in culture also presents advantages, including the possibility of targeting putative dormant epidermal stem cells. In the present study we compared the efficiency of transduction achieved with a third-generation of human immunodeficiency virus (HIV)-based lentiviral vector to that obtained with a Moloney murine leukemia oncoretroviral vector (MLV) on proliferating and quiescent human keratinocytes growing in vitro in standard Rheinwald and Green cultures as well as in confluent organotypic cultures. Each viral vector contained the enhanced green fluorescent protein (EGFP) as a reporter gene. The lentiviral vector, but not the MLV vector, led to EGFP expression both in nondividing and proliferating epidermal cell populations in vitro. This feature was clearly evident when direct targeting of human keratinocytes, forming part of the epidermal component of an organotypic skin culture, was attempted. Keratinocytes modified by both MLV and the lentiviral vector allowed long-term regeneration of genetically engineered human skin on the backs of immunodeficient nonobese diabetic/severe combined immunodeficiency disorders (NOD/SCID) mice. However, EGFP transgene expression in the context of the MLV (long-terminal repeat [LTR]-driven) or lentiviral vector (cytomegalovirus [CMV]-driven) demonstrated clear differences both in quantitative terms and in the in vivo localization pattern.

Entities:  

Mesh:

Year:  2003        PMID: 14577919     DOI: 10.1089/104303403322495089

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  5 in total

1.  Loss of transgene following ex vivo gene transfer is associated with a dominant Th2 response: implications for cutaneous gene therapy.

Authors:  Zhenmei Lu; Soosan Ghazizadeh
Journal:  Mol Ther       Date:  2007-03-13       Impact factor: 11.454

2.  Development of a bioengineered skin-humanized mouse model for psoriasis: dissecting epidermal-lymphocyte interacting pathways.

Authors:  Sara Guerrero-Aspizua; Marta García; Rodolfo Murillas; Luisa Retamosa; Nuria Illera; Blanca Duarte; Almudena Holguín; Susana Puig; Maria Isabel Hernández; Alvaro Meana; Jose Luis Jorcano; Fernando Larcher; Marta Carretero; Marcela Del Río
Journal:  Am J Pathol       Date:  2010-10-22       Impact factor: 4.307

3.  Efficient in vivo targeting of epidermal stem cells by early gestational intraamniotic injection of lentiviral vector driven by the keratin 5 promoter.

Authors:  Masayuki Endo; Philip W Zoltick; William H Peranteau; Antoneta Radu; Nidal Muvarak; Mayumi Ito; Zaixin Yang; George Cotsarelis; Alan W Flake
Journal:  Mol Ther       Date:  2007-10-09       Impact factor: 11.454

4.  Pseudotyped adeno-associated viral vector tropism and transduction efficiencies in murine wound healing.

Authors:  Sundeep G Keswani; Swathi Balaji; Louis Le; Alice Leung; Foong-Yen Lim; Mounira Habli; Helen N Jones; James M Wilson; Timothy M Crombleholme
Journal:  Wound Repair Regen       Date:  2012-06-19       Impact factor: 3.617

5.  Pseudotyped adeno-associated viral vectors for gene transfer in dermal fibroblasts: implications for wound-healing applications.

Authors:  Swathi Balaji; Alice King; Yashu Dhamija; Louis D Le; Aimen F Shaaban; Timothy M Crombleholme; Sundeep G Keswani
Journal:  J Surg Res       Date:  2013-04-03       Impact factor: 2.192

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.